Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis |
| |
Authors: | Piet Geusens Dirk Vanderschueren Anne Verstraeten Jan Dequeker Paul Devos Roger Bouillon |
| |
Institution: | (1) Arthritis and Metabolic Bone Disease Research Unit, Division of Rheumatology, U.Z. Pellenberg, B-3212 Pellenberg, K.U. Leuven, Belgium;(2) Department of Nuclear Medicine, U.Z. Pellenberg, B-3212 Pellenberg, K.U. Leuven, Belgium;(3) Laboratory for Experimental Medicine and Endocrinology, U.Z. Pellenberg, B-3212 Pellenberg, K.U. Leuven, Belgium |
| |
Abstract: | Summary We investigated the effect of short-term, 1,25-dihydroxyvitamin D3 therapy (4 μg/day for 4 days) on calcium metabolism in 27 postmenopausal women (11 cases with osteoporosis and 16 cases with
osteoarthritis). Bone mass at the axial and appendicular skeleton was higher in osteoarthritis than in osteoporosis. Initial
values of calcium metabolism were similar. Osteoporotic and osteoarthritic patients responded with a similar significant increase
in serum osteocalcin (+61% and +54%, respectively), fasting urinary calcium excretion (+178% and +124%, respectively) and
24 hour calcium excretion (+148% and +142%, respectively). Parathyroid hormone (PTH) levels decreased significantly in both
groups (−30% and −18%, respectively). Osteoclastic bone resorption, evaluated by urinary hydroxyproline excretion, was not
stimulated in either group. We conclude that in osteoporosis and also in osteoarthritis (1) 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) stimulation of osteoblast function is similar in production of osteocalcin; (2) the vitamin D target tissues react adequately
to 1,25(OH)2D3 stimulation; (3) short-term high dose of 1,25(OH)2D3 does not stimulate bone resorption; and (4) the differences in bone mass between osteoarthritis and osteoporosis are not
related to an alteration of the responsiveness to stimulation by 1,25 (OH)2D3. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|